This track will explore the latest breakthroughs in neuropharmacology, focusing on novel drug formulations and their mechanisms of action. Emphasis will be placed on the translation of these advancements into clinical practice for neurological disorders.

This session will address the complexities involved in the development of central nervous system drugs, including regulatory hurdles and market access. Discussions will highlight innovative strategies to overcome these challenges and expedite drug approval.

This track will delve into the pharmacological properties of neuroprotective agents and their potential applications in various neurological conditions. Presentations will focus on both preclinical and clinical studies that demonstrate efficacy and safety.

This session will examine the role of pharmacogenomics in personalizing treatment strategies for neurological disorders. Attendees will learn how genetic variations influence drug response and the implications for clinical practice.

This track will provide insights into the safety profiles and efficacy of current neurological therapeutics. Expert speakers will discuss methodologies for assessing drug safety and the importance of post-marketing surveillance.

This session will highlight cutting-edge methodologies in drug discovery specifically tailored for neurological applications. Topics will include high-throughput screening, in silico modeling, and the role of artificial intelligence in drug development.